ArticleCancers2021

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).

Victoria G Atkinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.